Shares of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) have earned an average broker rating score of 1.17 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.

Brokerages have set a 1-year consensus target price of $25.33 for the company and are anticipating that the company will post ($0.67) earnings per share for the current quarter, according to Zacks. Zacks has also given Syndax Pharmaceuticals an industry rank of 102 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th.

Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 14.04 on Monday. Syndax Pharmaceuticals has a one year low of $8.97 and a one year high of $18.03. The company’s market cap is $249.66 million. The stock has a 50 day moving average of $14.03 and a 200 day moving average of $13.31.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, August 9th. The company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.07. On average, analysts anticipate that Syndax Pharmaceuticals will post ($3.01) earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of SNDX. BlackRock Fund Advisors purchased a new stake in Syndax Pharmaceuticals during the second quarter valued at about $1,218,000. BlackRock Inc. increased its stake in Syndax Pharmaceuticals by 0.6% in the second quarter. BlackRock Inc. now owns 44,851 shares of the company’s stock valued at $442,000 after buying an additional 256 shares in the last quarter. BlackRock Investment Management LLC increased its stake in Syndax Pharmaceuticals by 99.4% in the second quarter. BlackRock Investment Management LLC now owns 36,068 shares of the company’s stock valued at $355,000 after buying an additional 17,982 shares in the last quarter. BlackRock Advisors LLC increased its stake in Syndax Pharmaceuticals by 232.7% in the second quarter. BlackRock Advisors LLC now owns 1,026,902 shares of the company’s stock valued at $10,115,000 after buying an additional 718,209 shares in the last quarter. Finally, Vanguard Group Inc. purchased a new stake in Syndax Pharmaceuticals during the second quarter valued at about $1,674,000. Hedge funds and other institutional investors own 57.64% of the company’s stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

5 Day Chart for NASDAQ:SNDX

Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.